TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
15.00
+0.09 (+0.60%)
At close: 4:01PM EDT

15.05 +0.05 (0.33%)
After hours: 7:58PM EDT

Stock chart is not supported by your current browser
Previous Close14.91
Open15.05
Bid14.98 x 1400
Ask15.00 x 1800
Day's Range14.85 - 15.13
52 Week Range14.04 - 25.96
Volume5,948,290
Avg. Volume10,874,635
Market Cap16.374B
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-2.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est19.90
Trade prices are not sourced from all markets
  • Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
    Zacksyesterday

    Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

    While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.

  • Reutersyesterday

    Teva stops testing its migraine drug as cluster headache treatment

    Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet the main goal of a late-stage trial. The drug, known generically as fremanezumab, competes with rival treatments from Eli Lilly & Co and Amgen Inc . Lilly in November received the U.S. Food and Drug Administration's "breakthrough" status for its migraine drug Emgality in treating episodic cluster headaches.

  • Reutersyesterday

    Teva to stop developing cluster headache treatment

    Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches. The company said the decision was taken after an analysis of late-stage ...

  • Business Wireyesterday

    Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the study’s primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met. As a result of the above, Teva is discontinuing the ENFORCE Phase III clinical trial program, which also includes a long-term safety study.

  • Business Wire2 days ago

    Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

  • Reuters5 days ago

    U.S. FDA approves Teva's generic nasal spray to treat opioid overdose

    Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received approval from the U.S. Food and Drug Administration (FDA) to market its generic nasal spray for opioid overdose, the health regulator said. This is the first approval of a generic naloxone nasal spray for use in a community setting by individuals without medical training, the FDA said in a statement. The FDA had tentatively approved Teva's generic naloxone nasal spray in June last year.

  • MarketWatch5 days ago

    FDA approves first generic naloxone nasal spray to treat opioid overdose

    The Food and Drug Administration has given Israeli drugmaker Teva Pharmaceuticals Inc. final approval to market the first generic naloxone nasal spray to treat opioid overdose, the agency announced Friday. The spray, currently sold under the brand name Narcan by Emergent BioSolutions Inc. subsidiary Adapt Pharma, is a life-saving medication that can stop or reverse the effects of an opioid overdose. Shares of Teva have lost 6.9% so far this year, while the S&P 500 has gained 15.9%. Shares of Emergent BioSolutions have fallen 10.6%. This marks the first time a generic naloxone nasal spray has been approved for use by people without medical training, though generic injectable naloxone products have been available for years. "In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone," said Douglas Throckmorton, deputy center director for regulatory programs in the FDA's Center for Drug Evaluation and Research, in a statement. The U.S. in the midst of a deadly opioid epidemic. Almost 400,000 people died from opioid overdose between 1999 and 2017, according to the Centers for Disease Control and Prevention.

  • Allergan Falls as Supreme Court Dismisses Restasis Litigation
    Zacks8 days ago

    Allergan Falls as Supreme Court Dismisses Restasis Litigation

    Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

  • Business Wire13 days ago

    Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of AndroGel ®i (testosterone gel) 1.62% CIII in the U.S. Testosterone Gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired), and hypogonadotropic hypogonadism (congenital or acquired). With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

  • BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
    Zacks13 days ago

    BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

    BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

  • 9 High-Risk Stocks to Buy for Massive Rewards
    InvestorPlace14 days ago

    9 High-Risk Stocks to Buy for Massive Rewards

    [Editor's note: This story was previously published in November 2018. It has since been updated and republished.]Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.Still, there's room in any investor's portfolio for higher-risk, higher-reward plays -- as long as those risks are understood.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn that vein, here are 10 stocks to buy that offer potentially significant rewards … and almost as much risk. None of these stocks should be a core part of a portfolio, and all have the potential to blow up in your face. * 10 Dow Jones Stocks Holding the Blue Chip Index Back But taking those risks also creates the possibility of a major reward. It's likely at least a few of these stocks will wind up big winners going forward. Teva Pharmaceutical (TEVA)Teva Pharmaceutical (NYSE:TEVA) isn't having a great year, down just about 7%.Teva has too much debt and too little growth. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. Bankruptcy likely isn't a near-term scenario but the current trajectory suggests it could occur down the line. In short, TEVA is a classic contrarian, "buy when there's blood in the streets" type of play. And there are reasons TEVA is one of these great (if risky) stocks to buy.While pressure has persisted on generic drugs, but it won't last forever.The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat. In my opinion, Teva is a better version of Valeant, but with an easier path back to normalcy.It's a risky path, but if it works TEVA could gain another 20%-plus simply by reaching a higher multiple and removing bankruptcy fears.Source: Shutterstock Scientific Games Corp (SGMS)The story already has played out somewhat at Scientific Games (NASDAQ:SGMS), which is up 14.23% so far this year. But the growth story isn't necessarily over.Only a few years ago, Scientific Games was a sleepy, low-growth provider of lottery tickets and terminals. But in quick succession, SciGames acquired slot machine manufacturers WMS Industries and Bally Technologies, the latter coming only months after Bally bought equipment maker and gaming table designer Shuffle Master. Scientific Games became the dominant supplier to the casino industry worldwide: a "one-stop shop" for casino floors.It also became one of the most indebted companies in the U.S. markets and still is. The combination of that debt and careful cost controls at casinos, particularly in the U.S., kept SGMS stock below $20 to start the year. * 8 Risky Stocks to Watch as Earnings Season Kicks Off But it now looks like the long-awaited "replacement cycle" of slot machines is arriving and that could be hugely beneficial for Scientific Games and its smaller, similar rival Everi Holdings Inc (NYSE:EVRI). And considering how much leverage is still on the balance sheet, there's a case for SGMS to clear $100 -- yes, $100 -- if profit growth accelerates.That's not a guarantee, obviously, but it's the nature of highly indebted companies. Leverage is a weight when those companies struggle, and it's a springboard when they grow.Source: Chesapeake Energy Chesapeake Energy (CHK)In the case of Chesapeake Energy Corporation (NYSE:CHK), leverage has been a weight. After optimism about stable energy prices and Chesapeake's improved balance sheet boosted CHK stock in 2017, it was nothing but downhill in 2018. CHK now trades up ,pre than 57% since the beginning of the year. This could be the upswing you've been waiting for.I think CHK is the best, if riskiest, of the stocks to buy on higher energy prices. At the least, Chesapeake has bought itself more time for those prices to work higher. It's also worth pointing out that Chesapeake bonds actually have been rather stable so far this year. Efficiency improvements at the wellhead have lowered costs as well.Chesapeake is a risky play, but the combination of debt on the balance sheet and leverage from higher energy prices mean that with a couple of changes, CHK could soar.Source: Web Summit Via Flickr Splunk (SPLK)Splunk (NASDAQ:SPLK), on the other hand, isn't the cheapest stock in its space or anywhere else. The high-flying "operational intelligence" software provider trades up nearly 30% since the beginning of the year alone.The valuation alone shows the risk in SPLK, which has pulled back from brief early-2014 highs above $100. But since that pullback, SPLK stock actually has been rather stable, as investors give the company time to grow into its valuation.Meanwhile, Splunk continues to be a likely acquisition target, with Cisco (NASDAQ:CSCO) cited as a potential buyer in June and International Business Machines (NYSE:IBM) long thought to be a logical acquirer. * 7 High-Risk Stocks With Big Potential Rewards Splunk is a classic growth stock in that it, too, is high-risk and high-reward. But it looks like one of the better growth stocks to buy in what might be an over-aggressive market at the moment.Source: Shutterstock Ship Finance International (SFL)The shipping space generally has been a "Bermuda Triangle" for investor capital, but Ship Finance International (NYSE:SFL) might be the exception to the rule.There's likely to be some near-term volatility and Ship Finance's dividend, which currently yields 10.95%, could be at risk, but it's still one of those great stocks to buy if you can handle the risk.But this also remains one of the best plays in shipping, available for a modest premium to book value and at low-teens multiple to earnings. The industry alone, and a heavily leveraged balance sheet, both show the risk.But if Ship Finance can make it through some choppy waters over the next few months, there's likely a nice return for shareholders on the other side. GW Pharmaceuticals (GWPH)There's no sector of the market more boom-and-bust than biotech and drug development. GW Pharmaceuticals (NASDAQ:GWPH) doubles down on that volatility by developing its drugs from marijuana.But GW Pharmaceuticals isn't one of those fly-by-night penny stocks to buy based on legalized weed. It's a $2.6 billion pharmaceutical company with a legitimate lead product candidate in Epidiolex, aimed to treat Dravet Syndrome and Lennox-Gastaut Syndrome. Sativex, used to treat multiple sclerosisSativex, used to treat multiple sclerosis spasticity, already is on the market. And another compound has potential uses to fight epilepsy and treat autism spectrum disorders. * 10 Medical Marijuana Stocks to Cure Your Portfolio Like most drug development plays, GWPH is high-risk. But there's reason for investors to hold long-term optimism toward the company's pipeline. Success in getting those drugs to market likely would make GWPH an acquisition target at some point suggesting a significant upside from current levels. If it happens, analysts see GWPH stock surging near 30%.That in turn, would suggest likely significant upside from current levels for GWPH stock.Source: Shutterstock Canadian Solar (CSIQ)Considering that solar power actually is gaining an increasing share of the U.S. market, in particular, it's surprising that solar stocks including Canadian Solar (NASDAQ:CSIQ) actually haven't done all that well. SolarCity had to be rescued by Tesla (NASDAQ:TSLA). First Solar (NASDAQ:FSLR) is down from multi-year highs despite the recent strength.There are risks for CSIQ, in particular. "Commoditization" and price pressure could hit margins. Still, demand for CSIQ equipment is growing, the stock isn't terribly highly valued, and it's lagged of late while FSLR, in particular, has risen.Solar stocks are likely to stay choppy for a while, but CSIQ should have some room to run if it can get through the second half of the year.Source: Helgi Halldorsson via Flickr Superior Industries International (SUP)Superior Industries International (NYSE:SUP) is on the move again. Shipments of the company's aluminum wheels hit a record last year and it's starting to pay off.Auto parts stocks as a whole have had trouble, driven by "peak auto" concerns in the space. Superior itself has had a couple of missteps that impacted margins, and profits. And with SUP one of the more indebted companies in the sector, both factors have had an amplified impact on Superior's share price. * 7 Biometric Stocks to Watch as AI Rises But there's a reason to see a reversal as well, which is what makes SUP one of the smart stocks to buy. Near-term auto sales may be coming down, particularly in the U.S.Last year's acquisition of European supplier UNIWHEELS improved Superior's position overseas. And there is room to improve execution, and hopefully, margins, going forward.SUP does have potential downside risk, particularly if global macro concerns arise, pressuring auto sales and dropping SUP earnings further. But for contrarians who think the auto parts selloff is overdone, SUP is one of the more intriguing plays.Source: Rob Wall via Flickr (Modified) Chegg (CHGG)Chegg (NYSE:CHGG) is another of the growth stocks to buy with a high valuation and a big opportunity. The company began as an online textbook rental company. But it wound up outsourcing that business to another provider and since has focused on becoming the dominant digital platform for U.S. college students.And Chegg is having some success. Revenues are growing and adjusted EBITDA has turned positive after years of losses. The company's tutors and study services businesses are growing rapidly, and it's becoming a fixture in the college landscape.There are risks here beyond valuation. Like so many companies, Amazon is a potential competitor down the line, given its efforts to offer free Prime services to college students. But at this point, it might simply be easier for Amazon to buy Chegg, rather than expend the resources to try and fight it.With each passing quarter, Chegg gets more and more entrenched. And that only serves to strengthen the bull case for CHGG stock.As of this writing, Vince Martin did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Cheap Stocks That Are Leading the Blue Chips * 7 Straight-A Stocks to Build a Portfolio Around * Forget the FANGs -- Buy These 5 Tech Stocks Instead Compare Brokers The post 9 High-Risk Stocks to Buy for Massive Rewards appeared first on InvestorPlace.

  • Business Wire15 days ago

    Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

    Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it has entered into a new $2.3 billion unsecured revolving credit facility, which replaces its existing $3.0 billion credit facility.

  • Business Wire16 days ago

    Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter 2019 financial results on Thursday, May 2, 2019 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. A live webcast of the call will also be available on Teva's website at: http://ir.tevapharm.com.

  • The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
    Zacks16 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

    The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

  • Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
    Zacks19 days ago

    Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

    Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

  • Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
    Zacks19 days ago

    Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

    Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

  • CNBC20 days ago

    Stocks making the biggest moves premarket: Tesla, Viacom, Intel, J&J, Amazon & more

    These are the stocks posting the largest moves before the bell.

  • Reuters20 days ago

    Oklahoma drops several claims in opioid case against J&J, Teva

    Oklahoma's attorney general on Thursday had dropped all but a single claim against Johnson & Johnson and Teva Pharmaceutical Industries Ltd in a closely watched lawsuit alleging the drugmakers helped fuel the U.S. opioid epidemic. The move by Oklahoma Attorney General Mike Hunter came ahead of an upcoming May 28 trial, the first in the United States to result from roughly 2,000 lawsuits seeking to hold manufacturers of painkillers responsible for contributing to the epidemic. Hunter dropped the claims after announcing last week that OxyContin maker Purdue Pharma LP had along with the wealthy Sackler family who own it reached a $270 million settlement.

  • Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
    Zacks22 days ago

    Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe

    Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.

  • 2 Incredibly Cheap Pharma Stocks to Buy Now
    Motley Fool23 days ago

    2 Incredibly Cheap Pharma Stocks to Buy Now

    Shares of Gilead Sciences and Teva Pharmaceutical Industries are bargains right now.

  • Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
    Business Wire24 days ago

    Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission (EC) has granted the Marketing Authorization for AJOVY (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month. AJOVY is a humanized monoclonal antibody (mAb) that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

  • BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?
    InvestorPlace24 days ago

    BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?

    The past three years have been tough for investors in Teva Pharmaceutical Industries (NYSE:TEVA). The share have gone from their 2015 peak near $72 to a current price below $16, slipping out of a rebound effort that took shape in 2018. TEVA stock has peeled back from last year's high near $26, after bottoming near $11 in late-2017.Nothing seems to excite investors for very long.Analysts -- some analysts anyway -- are starting to take notice of subtle changes, putting several upgrades in place during the first quarter of this year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMost of those calls are still cautious ones, with the most recent one from BMO Capital Markets being no exception to that norm. The analysts at Bank of Montreal (NYSE:BMO) see evidence of a turnaround taking shape, but remain concerned that Teva's generics business and pipeline aren't quite as robust as the firm would like.In taking a closer look at the analyst community's changing consensus, though, it's possible these professionals are quietly pointing toward more potential than most investors currently see in Teva stock. Disguised BullishnessBMO analyst Gary Nachman doesn't believe recent launches of Huntington's disease treatment Austedo and migraine treatment Ajovy will "be enough to put the overall company on a solid growth trajectory," adding concern about the limited "visibility on the generic pipeline, where we believe TEVA is behind its peers." * 7 Reasons to Buy Housing Stocks in 2019 Still, there's enough potential in Teva Pharmaceuticals stock for BMO to initiate coverage on it, rating it a Market Perform … a call that leaves the door wide open to updated ratings in either direction.Nachman had a valid point, too, about the company's generics pipeline. From what can be gleaned about it, it's not necessarily scintillating.That's not exactly news though, to investors or to the company, or to other analysts for that matter. That's been a lingering problem at Teva to most professional and amateur observers.It may also be the groundwork for upgrades driven by the very pipeline BMO is concerned about.Even if unintentionally, most other analysts are doing the same. As of the latest look, the pros collectively rate TEVA stock at only a little better than a "Hold" but simultaneously sport a consensus price target of $20.50. That's 30% better than the stock's current price. Click to EnlargeThe superficial mismatch isn't stunningly unusual; most stocks are priced below their consensus targets regardless of the collective buy/sell opinion on those names.This particular disparity, however, is also mismatched with the "read between the lines" rhetoric. Teva stock has been upgraded three times so far this year, with two new-coverage initiations at Hold that may be precursors to expected upgrades.If those upgrades are going to materialize, though, they're going to do so thanks to only a handful of names in the company's drug portfolio and pipeline. Identifying Growth DriversWhile its bench of drugs is deep, Teva's flagship product is multiple sclerosis drug Copaxone.In its prime, Copaxone had no peers. It's past its prime though, largely thanks to generic alternatives that have hit the market just in the past couple of years. Mylan (NASDAQ:MYL) got the nod from the FDA in late 2017; Novartis (NYSE:NVS) is in the MS treatment race with its own version of Copaxone as well.Those rival drugs have taken a measurable toll. In 2016, Teva sold $4.2 billion worth of Copaxone, but that volume was almost halved to a little less than $2.4 billion last year.The bulk of the adverse impact of the generic multiple sclerosis treatment, however, is likely in the rearview mirror. Going forward, Teva shouldn't be fighting as much of a headwind on at least that one front.In the meantime, Ajovy and Austedo may be bigger growth drivers than BMO's Nachman is currently be letting on.Migraine drug Ajovy taps into a relatively underserved market. While Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN)/Novartis are also in the same market with Emgality and Aimovig, respectively, analysts at Israel's IBI anticipates peak sales of between $1.6 billion and $2.4 billion for Teva's Ajovy. Meanwhile, RBC Capital Markets analyst Randall Stanicky forecasts peak sales of $1.3 billion for Austedo. * 10 Tech Stocks That Transformed Their Business That level of success, along with the rest of the company's portfolio and pipeline, should restore solid growth even as the benefit of Copaxone shrinks.Also keep an eye on subsidiary Anda, which saw sales growth of 26% last quarter, reaching $363 million.The upshot for owners of Teva stock is that it's crystal clear where growth needs to come from. It won't be difficult to see what's working, and what's not, given the relatively small portfolio and pipeline. Bottom Line on Teva StockAgain, without saying as much, most Teva stock analysts may be quietly expecting a respectable turnaround, but are thus far unwilling to say as much without more tangible proof it's taking shape.Analysts' careers don't just depend on quality analysis, but on being 'right' even if that standard is unspoken. These professionals may be cautiously leading investors to a marketwide conclusion that the forward-looking P/E of 6.0 for Teva stock is simply too cheap to pass up, given the potential -- even if not the assured promise -- of a turnaround.Undoubtedly though, the rhetoric about slowing Copaxone's deterioration and the growth of Austedo and Ajovy will help shape investors' and analysts' opinion. Investors would be wise to focus on those three drugs as a barometer of how the market feels about Teva stock.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 4 Pot Stocks That Could Be Fizzling Out * 7 Mid-Cap Growth Stocks That Could Be the Next Amazon or Netflix Compare Brokers The post BMO's Got A Point About Teva Stock, But Are Investors Willing To Listen? appeared first on InvestorPlace.

  • Business Wire24 days ago

    Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent EP 2 949 335 covering Teva’s COPAXONE® 40mg product in Europe. The Opposition Division will issue its written underlying rationale on the decision within a few months. The patent protects the three-times-weekly subcutaneous injection of 40 mg/mL (“40mgTIW”) of glatiramer acetate for the treatment of certain forms of multiple sclerosis.

  • Were Hedge Funds Right About Souring On Teva Pharmaceutical (TEVA)?
    Insider Monkey25 days ago

    Were Hedge Funds Right About Souring On Teva Pharmaceutical (TEVA)?

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
    Motley Fool25 days ago

    Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake

    There isn't a lot of interest on Wall Street for these out-of-favor stocks, but here's why you should consider them.